Galcanezumab treatment changes visual related EEG connectivity patterns in migraine patients.
Authors
La Rocca M, Laporta A, Clemente L, Ammendola E, Delussi MD, Ricci K, Tancredi G, Stramaglia S, de Tommaso M
Abstract
Monoclonal antibodies against calcitonin gene-related peptides (CGRP) are innovative therapies for migraine treatment. Although they are clinically effective, how anti-CGRP treatment reduces migraine attacks still remains unclear.
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the IASP Privacy Policy. By closing this banner, you agree to the use of cookies.Agree
